Julien Potet
Research Subjects
Julien Potet has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Alcoba
Médecins Sans Frontières, Operational Center Geneva, Geneva, Switzerland
3 shared publications Alexandra Kruse
Médecins Sans Frontières, Brussels, Belgium
2 shared publications- Koert Ritmeijer
Médecins Sans Frontières, Amsterdam, The Netherlands
2 shared publications - Margriet Den Boer
Médecins Sans Frontières , Plantage Middenlaan, Amsterdam , 1018 DD
2 shared publications - Abdulrazaq Garba Habib
Department of Medicine, Bayero University, Kano, Nigeria
1 shared publication Aboubacar Bengaly
Médecins Sans Frontières, Paoua, Central African Republic
1 shared publication
Latest Publications
- Open Access
- 31 March 2026
- Vol. 6 (1)
Prophylaxie post-exposition contre le virus Ebola : arguments en faveur d’un élargissement du rôle des anticorps monoclonaux dans un contexte d’accès limité
Alors que la maladie à virus Ebola (MVE) reste une menace majeure, des progrès récents ont permis l’homologation de plusieurs produits médicaux, en particulier le vaccin rVSVΔG-ZEBOV-GP (Ervebo) et deux traitements par anticorps monoclonaux, mAb114 (Ebanga) et REGN-EB3 (Inmazeb). Leur utilisation en prophylaxie post-exposition (PPE) reste cependant peu documentée. Notre revue narrative de la littérature et des lignes directrices proposées par des organisations en réponse aux épidémies d’Ebola vise à évaluer le potentiel du vaccin rVSVΔG-ZEBOV-GP et des anticorps monoclonaux mAb114 et REGN-EB3 pour une PPE suite à une exposition à haut risque d’infection. Très peu d’études ont été menées spécifiquement pour déterminer l’efficacité des vaccins ou des anticorps monoclonaux en PPE. Les données chez l’animal et chez l’homme suggèrent que le vaccin rVSVΔG-ZEBOV-GP n’offre qu’une protection limitée en PPE, bien qu’il puisse réduire la sévérité de la MVE si elle survient. Aucune des 34 personnes ayant reçu le vaccin dans le cadre de la PPE à ce jour n’a développé de MVE. Une étude rétrospective cas-témoins suggère une efficacité de seulement 16 % contre la survenue de la MVE lorsque le vaccin est administré pendant une période compatible avec la PPE. En revanche, les anticorps monoclonaux mAb114 et REGN-EB3, en raison de leur action immédiate par immunisation passive, semblent conférer une protection plus élevée contre la survenue de la MVE après une exposition à haut risque, avec une survie à 100 % en modèle animal, bien que les données cliniques humaines restent rares avec seulement 23 cas d’utilisation recensés en PPE et aucune survenue de MVE. L’accès aux anticorps monoclonaux pour les membres de la communauté ayant fait l’objet d’une exposition à haut risque devrait être assuré, tout en optimisant les critères d’évaluation du risque. Des recherches supplémentaires, notamment sur l’interaction entre vaccination et administration d’anticorps, sont essentielles pour déterminer les stratégies de PPE les plus efficaces. Enfin, un stock d’urgence d’anticorps monoclonaux et une amélioration du suivi des contacts sont indispensables pour renforcer la réponse aux épidémies. Malgré les limites des données actuelles, les anticorps monoclonaux devraient être envisagés comme option prioritaire en PPE pour les personnes à haut risque.
- 31 March 2026
- Vol. 6 (1)
Open AccessProphylaxie post-exposition contre le virus Ebola : arguments en faveur d’un élargissement du rôle des anticorps monoclonaux dans un contexte d’accès limité
Alors que la maladie à virus Ebola (MVE) reste une menace majeure, des progrès récents ont permis l’homologation de plusieurs produits médicaux, en particulier le vaccin rVSVΔG-ZEBOV-GP (Ervebo) et deux traitements par anticorps monoclonaux, mAb114 (Ebanga) et REGN-EB3 (Inmazeb). Leur utilisation en prophylaxie post-exposition (PPE) reste cependant peu documentée. Notre revue narrative de la littérature et des lignes directrices proposées par des organisations en réponse aux épidémies d’Ebola vise à évaluer le potentiel du vaccin rVSVΔG-ZEBOV-GP et des anticorps monoclonaux mAb114 et REGN-EB3 pour une PPE suite à une exposition à haut risque d’infection. Très peu d’études ont été menées spécifiquement pour déterminer l’efficacité des vaccins ou des anticorps monoclonaux en PPE. Les données chez l’animal et chez l’homme suggèrent que le vaccin rVSVΔG-ZEBOV-GP n’offre qu’une protection limitée en PPE, bien qu’il puisse réduire la sévérité de la MVE si elle survient. Aucune des 34 personnes ayant reçu le vaccin dans le cadre de la PPE à ce jour n’a développé de MVE. Une étude rétrospective cas-témoins suggère une efficacité de seulement 16 % contre la survenue de la MVE lorsque le vaccin est administré pendant une période compatible avec la PPE. En revanche, les anticorps monoclonaux mAb114 et REGN-EB3, en raison de leur action immédiate par immunisation passive, semblent conférer une protection plus élevée contre la survenue de la MVE après une exposition à haut risque, avec une survie à 100 % en modèle animal, bien que les données cliniques humaines restent rares avec seulement 23 cas d’utilisation recensés en PPE et aucune survenue de MVE. L’accès aux anticorps monoclonaux pour les membres de la communauté ayant fait l’objet d’une exposition à haut risque devrait être assuré, tout en optimisant les critères d’évaluation du risque. Des recherches supplémentaires, notamment sur l’interaction entre vaccination et administration d’anticorps, sont essentielles pour déterminer les stratégies de PPE les plus efficaces. Enfin, un stock d’urgence d’anticorps monoclonaux et une amélioration du suivi des contacts sont indispensables pour renforcer la réponse aux épidémies. Malgré les limites des données actuelles, les anticorps monoclonaux devraient être envisagés comme option prioritaire en PPE pour les personnes à haut risque.
- Open Access
- 6 June 2024
- Published by BMJ in Emergency Medicine Journal
- Vol. 41 (9) , 560
Debate-Pro: manufacturers should assess the long-term stability of their antivenoms
- 6 June 2024
- Published by BMJ in Emergency Medicine Journal
- Vol. 41 (9) , 560
Open AccessDebate-Pro: manufacturers should assess the long-term stability of their antivenoms
- Open Access
- 20 December 2022
- Published by Elsevier in Toxicon: X
- Vol. 17, 100146
Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues
- 20 December 2022
- Published by Elsevier in Toxicon: X
- Vol. 17, 100146
Open AccessSnakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues
- Open Access
- 18 December 2021
- Published by Elsevier in Toxicon: X
- Vol. 13, 100089
Snakebite envenoming in humanitarian crises and migration: A scoping review and the Médecins Sans Frontières experience
- 18 December 2021
- Published by Elsevier in Toxicon: X
- Vol. 13, 100089
Open AccessSnakebite envenoming in humanitarian crises and migration: A scoping review and the Médecins Sans Frontières experience
- Open Access
- 26 October 2021
- Published by Elsevier in Toxicon: X
- Vol. 12, 100086
Access to antivenoms in the developing world: A multidisciplinary analysis
- 26 October 2021
- Published by Elsevier in Toxicon: X
- Vol. 12, 100086
Open AccessAccess to antivenoms in the developing world: A multidisciplinary analysis
- Open Access
- 25 October 2021
- Published by BMJ in BMJ Global Health
- Vol. 6 (10) , e006913
Snakebites and COVID-19: two crises, one research and development opportunity
- 25 October 2021
- Published by BMJ in BMJ Global Health
- Vol. 6 (10) , e006913
Open AccessSnakebites and COVID-19: two crises, one research and development opportunity
- Open Access
- 19 August 2021
- Published by BMJ in BMJ Global Health
- Vol. 6 (8) , e006835
Control of visceral leishmaniasis in East Africa: fragile progress, new threats
- 19 August 2021
- Published by BMJ in BMJ Global Health
- Vol. 6 (8) , e006835
Open AccessControl of visceral leishmaniasis in East Africa: fragile progress, new threats
- Open Access
- 24 June 2019
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 13 (6) , e0007551
Reviewing evidence of the clinical effectiveness of commercially available antivenoms in sub-Saharan Africa identifies the need for a multi-centre, multi-antivenom clinical trial
Snakebite envenoming kills more than more than 20,000 people in Sub-Saharan Africa every year. Poorly regulated markets have been inundated with low-price, low-quality antivenoms. This review aimed to systematically collect and analyse the clinical data on all antivenom products now available in markets of sub-Saharan Africa. Our market analysis identified 12 polyspecific and 4 monospecific antivenom products in African markets. Our search strategy was first based on a systematic search of publication databases, followed by manual searches and discussions with experts. All types of data, including programmatic data, were eligible. All types of publications were eligible, including grey literature. Cohorts of less than 10 patients were excluded. 26 publications met the inclusion criteria. Many publications had to be excluded because clinical outcomes were not clearly linked to a specific product. Our narrative summaries present product-specific clinical data in terms of safety and effectiveness against the different species and envenoming syndromes. Three products (EchiTabPlus, EchiTabG, SAIMR-Echis-monovalent) were found to have been tested in robust clinical studies and found effective against envenoming caused by the West African carpet viper (Echis ocellatus). Four products (Inoserp-Panafricain, Fav-Afrique, SAIMR-Polyvalent, Antivipmyn-Africa) were found to have been evaluated only in observational single-arm studies, with varying results. For nine other products, there are either no data in the public domain, or only negative data suggesting a lack of effectiveness. Clinical data vary among the different antivenom products currently in African markets. Some products are available commercially although they have been found to lack effectiveness. The World Health Organization should strengthen its capacity to assess antivenom products, support antivenom manufacturers, and assist African countries and international aid organizations in selecting appropriate quality antivenoms. Snakebite envenomation represents one of the most neglected tropical medical conditions worldwide. Despite high levels of morbidity and mortality associated with snakebite, its neglected nature has compromised the availability and evaluation of antivenom treatment. This review was initiated by Médecins Sans Frontières’ / Doctors Without Borders (MSF) Access Campaign, as the existing antivenom access crisis in sub-Saharan Africa was deepening. This study sought to review the clinical data pertaining to each antivenom product currently available for use in sub-Saharan Africa. 16 different antivenoms were identified. A total of 26 studies met the inclusion criteria. Given the heterogeneity of study methodology and quality, data for individual antivenoms are presented in the form of a narrative analysis. Only two studies reported clinical data collected from randomized controlled trials. Consistent monitoring of the side effects of antivenom treatment was lacking. The absence of good quality data for the majority of antivenoms in sub-Saharan Africa is a major concern. Further robust data collection is required, while urgent investments are needed at the global level to ensure a sustained production of safe and effective antivenom treatment, and its affordable access across sub-Saharan Africa.
- 24 June 2019
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 13 (6) , e0007551
Open AccessReviewing evidence of the clinical effectiveness of commercially available antivenoms in sub-Saharan Africa identifies the need for a multi-centre, multi-antivenom clinical trial
Snakebite envenoming kills more than more than 20,000 people in Sub-Saharan Africa every year. Poorly regulated markets have been inundated with low-price, low-quality antivenoms. This review aimed to systematically collect and analyse the clinical data on all antivenom products now available in markets of sub-Saharan Africa. Our market analysis identified 12 polyspecific and 4 monospecific antivenom products in African markets. Our search strategy was first based on a systematic search of publication databases, followed by manual searches and discussions with experts. All types of data, including programmatic data, were eligible. All types of publications were eligible, including grey literature. Cohorts of less than 10 patients were excluded. 26 publications met the inclusion criteria. Many publications had to be excluded because clinical outcomes were not clearly linked to a specific product. Our narrative summaries present product-specific clinical data in terms of safety and effectiveness against the different species and envenoming syndromes. Three products (EchiTabPlus, EchiTabG, SAIMR-Echis-monovalent) were found to have been tested in robust clinical studies and found effective against envenoming caused by the West African carpet viper (Echis ocellatus). Four products (Inoserp-Panafricain, Fav-Afrique, SAIMR-Polyvalent, Antivipmyn-Africa) were found to have been evaluated only in observational single-arm studies, with varying results. For nine other products, there are either no data in the public domain, or only negative data suggesting a lack of effectiveness. Clinical data vary among the different antivenom products currently in African markets. Some products are available commercially although they have been found to lack effectiveness. The World Health Organization should strengthen its capacity to assess antivenom products, support antivenom manufacturers, and assist African countries and international aid organizations in selecting appropriate quality antivenoms. Snakebite envenomation represents one of the most neglected tropical medical conditions worldwide. Despite high levels of morbidity and mortality associated with snakebite, its neglected nature has compromised the availability and evaluation of antivenom treatment. This review was initiated by Médecins Sans Frontières’ / Doctors Without Borders (MSF) Access Campaign, as the existing antivenom access crisis in sub-Saharan Africa was deepening. This study sought to review the clinical data pertaining to each antivenom product currently available for use in sub-Saharan Africa. 16 different antivenoms were identified. A total of 26 studies met the inclusion criteria. Given the heterogeneity of study methodology and quality, data for individual antivenoms are presented in the form of a narrative analysis. Only two studies reported clinical data collected from randomized controlled trials. Consistent monitoring of the side effects of antivenom treatment was lacking. The absence of good quality data for the majority of antivenoms in sub-Saharan Africa is a major concern. Further robust data collection is required, while urgent investments are needed at the global level to ensure a sustained production of safe and effective antivenom treatment, and its affordable access across sub-Saharan Africa.
- 1 April 2013
- Published by JLE in Medecine Et Sante Tropicales
- Vol. 23 (2) , 227-228
Buruli ulcers: an advocacy agenda to improve its control
Doctors Without Borders (Médecins Sans Frontières) has developed an advocacy agenda in Cameroon to better meet its patients' needs and to simplify control of Buruli ulcers. This agenda is based on 4 priorities: diagnostic (development of a clinical score), chemotherapeutic (to envision drug administration at home, without daily hospital visits), dressings, and HIV coinfection. These priority objectives should make it possible to reduce the duration of hospitalization and limit the need for surgery.
- 1 April 2013
- Published by JLE in Medecine Et Sante Tropicales
- Vol. 23 (2) , 227-228
Buruli ulcers: an advocacy agenda to improve its control
Doctors Without Borders (Médecins Sans Frontières) has developed an advocacy agenda in Cameroon to better meet its patients' needs and to simplify control of Buruli ulcers. This agenda is based on 4 priorities: diagnostic (development of a clinical score), chemotherapeutic (to envision drug administration at home, without daily hospital visits), dressings, and HIV coinfection. These priority objectives should make it possible to reduce the duration of hospitalization and limit the need for surgery.
- 1 December 2012
- Published by Elsevier in Feuillets de Radiologie
- Vol. 52 (6) , 307-313
Place de l’IRM dans la prise en charge des lésions méniscales instables
- 1 December 2012
- Published by Elsevier in Feuillets de Radiologie
- Vol. 52 (6) , 307-313
Place de l’IRM dans la prise en charge des lésions méniscales instables